Factors influencing individualized treatment selection in CLL | Anne-Sophie Michallet
EHA 2025 • DISEASE STATE • PHASE • Video
Anne-Sophie Michallet
Watch the recorded session from the BeOne-sponsored Satellite Symposium from EHA2025, in which Anne-Sophie Michallet explored the factors that influence treatment selection decisions in first and later lines of therapy for patients with CLL.
Related Content
CONGRESS
Updated safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström’s macroglobulinemia
Updated safety and antileukemic activity data for sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Updated safety & antileukemic activity data of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia unfit for intensive chemotherapy
This website is intended exclusively for healthcare professionals and is provided for scientific exchange and educational purposes only. It is not intended for patients or the general public and does not constitute advertising, promotional activity or medical advice.
Content may include information about products, indications or uses that are not approved in all countries or regions, and may be subject to local regulatory requirements.
By continuing, you confirm that you are a healthcare professional and acknowledge the above.
You are now leaving the website
This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.
This link will take you to a third-party website outside of beonemedaffairs.com.
[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.
By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.
Do you want to leave beonemedaffairs.com
You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed
